Search Results: Treatment + Breast Cancer + Stage 4 (12 results)
Study of a New Treatment Called TNG348 in People with Advanced or Metastatic Cancer and with a BRCA1 or BRCA2 Mutation or HRD Positive Tumor
https://www.facingourrisk.org/research-clinical-trials/study/296/study-of-a-new-treatment-called-tng348-in-people-with-advanced-or-metastatic-cancer-and-with-a-brca1-or-brca2-mutation-or-hrd-positive-tumor
Treatment
Treatment for patients who have advanced breast, ovarian, pancreatic, and prostate cancer and a BRCA1 or BRCA2 mutation or have an HRD positive tumor
The study will test the safety and effectiveness of a new drug called TNG348 used alone or in combination with Olaparib (a PARP inhibitor.) The study is for patients who have advanced breast, ovarian, pancreatic, and prostate cancer and a BRCA1 or BRCA2 mutation or have an HRD positive tumor.
Studies for People with ER-Positive, HER2-Negative Advanced or Metastatic Breast Cancer (TACTIVE-U)
https://www.facingourrisk.org/research-clinical-trials/study/279/treatment-studies-for-people-with-er-positive-her2-negative-advanced-or-metastatic-breast-cancer-tactive-u
Treatment
Treatment for ER-positive, HER2-negative metastatic breast cancer
Researchers at Pfizer and Arvinas are conducting the TACTIVE-U studies for people with ER-positive, HER2-negative advanced or metastatic breast cancer who have received at least one prior round of treatment and no more than two prior rounds of treatments for advanced or metastatic disease. One of these rounds of treatment must have included a CDK4/6 inhibitor (e.g., Kisqali, Verzenio, Ibrance). The TACTIVE-U studies are looking at the safety of an oral study medicine, ARV-471 (also known as vepdegestrant), and how well it works when combined with other breast cancer medicines.
A clinical trial for people with ER-positive, HER2-negative advanced (locally advanced or metastatic) breast cancer: VERITAC-2
https://www.facingourrisk.org/research-clinical-trials/study/269/studies-for-people-with-er-positive-her2-negative-advanced-or-metastatic-breast-cancer-veritac-studies
Treatment
A clinical trial for ER-positive, HER2-negative advanced breast cancer
Researchers at Pfizer and Arvinas are conducting the VERITAC-2 cinical trial for people with ER-positive, HER2-negative advanced (locally advanced or metastatic) breast cancer that has profressed after previous treatment. This clinical trial is specifically for people who have already been treated with CDK4/6 inhibitor* therapy in combination with hormone therapy for their locoregional recurrent/metastatic disease.
* CDK4/6 inhibitors include medications called palbociclib (IBRANCE®), ribociclib (KISQALI®), and abemaciclib (Verzenio®).
Combining the Immunotherapy Dostarlimab and PARP Inhibitor Niraparib for Advanced or Metastatic Breast, Ovarian or Pancreatic Cancer with an Inherited or Tumor BRCA Mutation
https://www.facingourrisk.org/research-clinical-trials/study/231/immunotherapy-and-parp-inhibitor-for-advanced-or-metastatic-breast-ovarian-or-pancreatic-cancer-with-a-brca-mutation
Treatment
Treatment study for people with advanced breast, ovarian or pancreatic cancer and an inherited or tumor BRCA mutation
This study is looking at the effectiveness of combining a PARP inhibitor called niraparib and an immunotherapy called dostarlimab for treating people with an inherited BRCA mutation (found with genetic testing) or a tumor mutation (found through tumor testing) who have breast, pancreatic, ovarian, fallopian tube or primary peritoneal cancer that is metastatic or advanced and cannot be removed by surgery (unresectable).
Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)
https://www.facingourrisk.org/research-clinical-trials/study/282/study-of-the-parp-inhibitor-azd9574-alone-and-combined-with-other-cancer-medicines-to-treat-people-with-advanced-solid-cancers-certis1-study
Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas
This research involves studying a drug called AZD9574 on its own and in combination with other anti-cancer drugs in people with advanced cancer that has come back or progressed. AZD9574 is a type of targeted therapy known as a PARP inhibitor. The study aims to understand the safety, tolerance, how the drug moves in the body, how it affects the body, and its initial effectiveness.
Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib
https://www.facingourrisk.org/research-clinical-trials/study/230/treating-metastatic-solid-tumors-with-an-inherited-or-acquired-gene-mutation-using-the-parp-inhibitor-talazoparib
Treatment
Treatment study for people with advanced solid tumors
This study is looking whether the drug Talazoparib (also known as Talzenna) is safe and effective for treating people with advanced solid cancers (including breast, gastric, ovarian, pancreatic, prostate or other solid tumors) in people with an inherited mutation (found through genetic testing) or an acquired mutation (found with biomarker testing) in ATM, ATR, BRCA1, BRCA2, BRIP1, BAP1, BARD1, CDK12, CHEK1, CHEK2, IDH1, IDH2, MRE11A, NBN, PALB2, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD54L or other genes.
NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/204/nuv-868-alone-and-in-combination-with-parp-inhibitors-in-patients-with-advanced-solid-tumors
Treatment
Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer
This study will test how safe and effective the experimental drug NUV-868 is by itself and in combination with a PARP inhibitor in people with advanced solid tumors. The first part of the study will include people with any solid tumor type, and the second part will include people with triple-negative breast, ovarian, pancreatic or prostate cancers only.
SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells
https://www.facingourrisk.org/research-clinical-trials/study/117/sharon-a-clinical-trial-for-metastatic-cancer-with-an-inherited-brca-or-palb2-mutation-using-chemotherapy-and-patients-own-stem-cells
Treatment
Advanced pancreatic cancer or stage 4 breast cancer in people with a BRCA1 or BRCA2 mutation
The purpose of this study is to see whether the combination of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous (self) bone marrow stem cell infusion, is safe and effective for treating patients with advanced pancreatic cancer or Stage IV, HER2-negative breast cancer who have a BRCA1, BRCA2 or PALB2 inherited mutation. All of these treatments are given intravenously (by vein). This study is open to people who have already received a PARP inhibitor, as well as those who have not. There are no restrictions on the number of prior treatments a patient has received before enrolling.
Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)
https://www.facingourrisk.org/research-clinical-trials/study/176/investigational-parp-inhibitor-azd5305-alone-or-combined-with-other-anti-cancer-agents-in-people-with-advanced-solid-tumors-petra
Treatment
Advanced ovarian, breast, prostate or pancreatic cancer
PETRA is studying a new PARP inhibitor AZD5305 taken either alone or combined with other treatments in people with advanced ovarian, breast, prostate or pancreatic cancer with an inherited or tumor mutation in: BRCA1/2, PALB2, RAD51C or RAD51D. The treaments participants receive will depend on their cancer type, mutation and when they join the study.
Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/157/treatment-with-atr-inhibitor-for-advanced-or-metastatic-solid-tumors
Treatment
Advanced solid tumors
This study will look at how well a new oral targeted therapy known as an ATR inhibitor works on advanced or metastatic solid tumors with mutations in genes linked to DNA damage repair. The study will look at response to treatment with the drug ART0380 in combination with the chemotherapy agent, gemcitabine.
Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations
https://www.facingourrisk.org/research-clinical-trials/study/100/talazoparib-for-people-with-metastatic-breast-cancer-who-have-acquired-somatic-brca-mutations
Treatment
This is a study for patients with metastatic breast cancer who do not have an inherited mutation in BRCA1 or BRCA2 but who are are found to have a BRCA1 or BRCA2 acquired tumor mutation (somatic mutation) found through liquid biopsy. Patients are treated with talazoparib, a well-tolerated oral PARP inhibitor that targets the BRCA1/2 mutation to determine whether this treatment (which is already approved for germline BRCA1/2 carriers) is effective in this population.
A Randomized Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Breast, Ovarian, Prostate and Pancreatic Cancer Patients
https://www.facingourrisk.org/research-clinical-trials/study/102/a-randomized-study-of-an-ehealth-delivery-alternative-for-cancer-genetic-testing-for-hereditary-predisposition-in-metastatic-breast-ovarian-prostate-and-pancreatic-cancer-patients-e-reach
Treatment
Genetic testing can be helpful to identify potential targeted treatments for some patients with metastatic cancer. But some patients have a hard time getting easy and fast testing. This study is looking at using web options to increase access to testing AND patients in this study can get genetic counseling and testing in their home! For more information visit the E-Reach registration page.
Additional Results on Clinicaltrials.gov Treatment + Breast Cancer + Stage 4
241 results
Study of Palliative Radiation Combined With Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer
NCT ID: NCT04990921 (https://classic.clinicaltrials.gov/show/NCT04990921)
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
NCT ID: NCT04923542 (https://classic.clinicaltrials.gov/show/NCT04923542)
Combined Immunotherapies in Metastatic ER+ Breast Cancer
NCT ID: NCT04563507 (https://classic.clinicaltrials.gov/show/NCT04563507)
Vaccination With Flt3L, Radiation, and Poly-ICLC
NCT ID: NCT03789097 (https://classic.clinicaltrials.gov/show/NCT03789097)
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
NCT ID: NCT04837209 (https://classic.clinicaltrials.gov/show/NCT04837209)
Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)
NCT ID: NCT05374915 (https://classic.clinicaltrials.gov/show/NCT05374915)
Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases
NCT ID: NCT03796273 (https://classic.clinicaltrials.gov/show/NCT03796273)
A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain
NCT ID: NCT05892068 (https://classic.clinicaltrials.gov/show/NCT05892068)
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
NCT ID: NCT04348747 (https://classic.clinicaltrials.gov/show/NCT04348747)
Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer
NCT ID: NCT04120246 (https://classic.clinicaltrials.gov/show/NCT04120246)
A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
NCT ID: NCT04521764 (https://classic.clinicaltrials.gov/show/NCT04521764)
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
NCT ID: NCT06026657 (https://classic.clinicaltrials.gov/show/NCT06026657)
GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
NCT ID: NCT03765983 (https://classic.clinicaltrials.gov/show/NCT03765983)
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
NCT ID: NCT04899908 (https://classic.clinicaltrials.gov/show/NCT04899908)
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
NCT ID: NCT04616248 (https://classic.clinicaltrials.gov/show/NCT04616248)
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
NCT ID: NCT05378464 (https://classic.clinicaltrials.gov/show/NCT05378464)
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
NCT ID: NCT04683679 (https://classic.clinicaltrials.gov/show/NCT04683679)
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
NCT ID: NCT04020575 (https://classic.clinicaltrials.gov/show/NCT04020575)
Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC
NCT ID: NCT05464082 (https://classic.clinicaltrials.gov/show/NCT05464082)
An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis
NCT ID: NCT05376878 (https://classic.clinicaltrials.gov/show/NCT05376878)
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
NCT ID: NCT05756166 (https://classic.clinicaltrials.gov/show/NCT05756166)
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
NCT ID: NCT03213041 (https://classic.clinicaltrials.gov/show/NCT03213041)
Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition
NCT ID: NCT04965688 (https://classic.clinicaltrials.gov/show/NCT04965688)
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer
NCT ID: NCT05098210 (https://classic.clinicaltrials.gov/show/NCT05098210)
INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study
NCT ID: NCT04445844 (https://classic.clinicaltrials.gov/show/NCT04445844)
BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy
NCT ID: NCT04454528 (https://classic.clinicaltrials.gov/show/NCT04454528)
An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improving Survival in Patients With Brain Metastases From Breast or Lung Cancer
NCT ID: NCT06315296 (https://classic.clinicaltrials.gov/show/NCT06315296)
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
NCT ID: NCT03808337 (https://classic.clinicaltrials.gov/show/NCT03808337)
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
NCT ID: NCT05673200 (https://classic.clinicaltrials.gov/show/NCT05673200)
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
NCT ID: NCT05491226 (https://classic.clinicaltrials.gov/show/NCT05491226)
GammaPod Dose Escalation Radiation for Early Stage Breast Cancer
NCT ID: NCT04234386 (https://classic.clinicaltrials.gov/show/NCT04234386)
Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer
NCT ID: NCT03801369 (https://classic.clinicaltrials.gov/show/NCT03801369)
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
NCT ID: NCT05534438 (https://classic.clinicaltrials.gov/show/NCT05534438)
Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers
NCT ID: NCT05846789 (https://classic.clinicaltrials.gov/show/NCT05846789)
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
NCT ID: NCT03742102 (https://classic.clinicaltrials.gov/show/NCT03742102)
Definitive Radiation for High-Risk Spine Metastases
NCT ID: NCT06165419 (https://classic.clinicaltrials.gov/show/NCT06165419)
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
NCT ID: NCT05319873 (https://classic.clinicaltrials.gov/show/NCT05319873)
Oncoplastic Partial Mastectomy With Intraoperative Radiation Therapy (IORT) in Early Stage Breast Cancer Patients With Prior History of Chest Wall Radiation.
NCT ID: NCT05289466 (https://classic.clinicaltrials.gov/show/NCT05289466)
Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
NCT ID: NCT05954143 (https://classic.clinicaltrials.gov/show/NCT05954143)
Her2-BATS and Pembrolizumab in Metastatic Breast Cancer
NCT ID: NCT03272334 (https://classic.clinicaltrials.gov/show/NCT03272334)
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases
NCT ID: NCT03696030 (https://classic.clinicaltrials.gov/show/NCT03696030)
Losartan in Prevention of Radiation-Induced Heart Failure
NCT ID: NCT05607017 (https://classic.clinicaltrials.gov/show/NCT05607017)
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
NCT ID: NCT04647916 (https://classic.clinicaltrials.gov/show/NCT04647916)
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
NCT ID: NCT05837767 (https://classic.clinicaltrials.gov/show/NCT05837767)
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
NCT ID: NCT04588545 (https://classic.clinicaltrials.gov/show/NCT04588545)
Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases
NCT ID: NCT04711824 (https://classic.clinicaltrials.gov/show/NCT04711824)
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
NCT ID: NCT06072612 (https://classic.clinicaltrials.gov/show/NCT06072612)
A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer
NCT ID: NCT05190770 (https://classic.clinicaltrials.gov/show/NCT05190770)
A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer
NCT ID: NCT05412225 (https://classic.clinicaltrials.gov/show/NCT05412225)
Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients With Pencil Beam Scanning Proton Therapy
NCT ID: NCT06006806 (https://classic.clinicaltrials.gov/show/NCT06006806)
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
NCT ID: NCT05372640 (https://classic.clinicaltrials.gov/show/NCT05372640)
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
NCT ID: NCT03449238 (https://classic.clinicaltrials.gov/show/NCT03449238)
Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer
NCT ID: NCT02778685 (https://classic.clinicaltrials.gov/show/NCT02778685)
Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy
NCT ID: NCT05747794 (https://classic.clinicaltrials.gov/show/NCT05747794)
Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones
NCT ID: NCT04090398 (https://classic.clinicaltrials.gov/show/NCT04090398)
Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
NCT ID: NCT03606967 (https://classic.clinicaltrials.gov/show/NCT03606967)
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After progrEssion on ENhertu (SATEEN)
NCT ID: NCT06100874 (https://classic.clinicaltrials.gov/show/NCT06100874)
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
NCT ID: NCT04265872 (https://classic.clinicaltrials.gov/show/NCT04265872)
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
NCT ID: NCT03694756 (https://classic.clinicaltrials.gov/show/NCT03694756)
Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial
NCT ID: NCT03075072 (https://classic.clinicaltrials.gov/show/NCT03075072)
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT ID: NCT05950945 (https://classic.clinicaltrials.gov/show/NCT05950945)
Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer
NCT ID: NCT06027268 (https://classic.clinicaltrials.gov/show/NCT06027268)
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
NCT ID: NCT05826964 (https://classic.clinicaltrials.gov/show/NCT05826964)
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
NCT ID: NCT04673448 (https://classic.clinicaltrials.gov/show/NCT04673448)
Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer
NCT ID: NCT04270149 (https://classic.clinicaltrials.gov/show/NCT04270149)
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
NCT ID: NCT04946864 (https://classic.clinicaltrials.gov/show/NCT04946864)
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
NCT ID: NCT06246968 (https://classic.clinicaltrials.gov/show/NCT06246968)
Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer
NCT ID: NCT05633979 (https://classic.clinicaltrials.gov/show/NCT05633979)
Evaluation of a Once Per Day Regimen of Accelerated Partial Breast Irradiation for Improved Breast Appearance in Patients With Low Risk, Hormone Responsive Breast Cancer
NCT ID: NCT06008158 (https://classic.clinicaltrials.gov/show/NCT06008158)
A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
NCT ID: NCT04699630 (https://classic.clinicaltrials.gov/show/NCT04699630)
Prospective Evaluation of Targeted Axillary Dissection (TAD)
NCT ID: NCT04998682 (https://classic.clinicaltrials.gov/show/NCT04998682)
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
NCT ID: NCT04315233 (https://classic.clinicaltrials.gov/show/NCT04315233)
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
NCT ID: NCT03742245 (https://classic.clinicaltrials.gov/show/NCT03742245)
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
NCT ID: NCT03428802 (https://classic.clinicaltrials.gov/show/NCT03428802)
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
NCT ID: NCT03971409 (https://classic.clinicaltrials.gov/show/NCT03971409)
Scalp Cooling in MBC
NCT ID: NCT04986579 (https://classic.clinicaltrials.gov/show/NCT04986579)
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
NCT ID: NCT04333706 (https://classic.clinicaltrials.gov/show/NCT04333706)
Preoperative Irradiation for Stage I Breast Cancer
NCT ID: NCT05464667 (https://classic.clinicaltrials.gov/show/NCT05464667)
Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling
NCT ID: NCT04965064 (https://classic.clinicaltrials.gov/show/NCT04965064)
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
NCT ID: NCT04222413 (https://classic.clinicaltrials.gov/show/NCT04222413)
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
NCT ID: NCT04478279 (https://classic.clinicaltrials.gov/show/NCT04478279)
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy
NCT ID: NCT05703269 (https://classic.clinicaltrials.gov/show/NCT05703269)
Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer
NCT ID: NCT05553522 (https://classic.clinicaltrials.gov/show/NCT05553522)
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
NCT ID: NCT01174121 (https://classic.clinicaltrials.gov/show/NCT01174121)
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
NCT ID: NCT04703920 (https://classic.clinicaltrials.gov/show/NCT04703920)
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
NCT ID: NCT05095207 (https://classic.clinicaltrials.gov/show/NCT05095207)
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
NCT ID: NCT04090567 (https://classic.clinicaltrials.gov/show/NCT04090567)
Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NCT ID: NCT04588246 (https://classic.clinicaltrials.gov/show/NCT04588246)
Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
NCT ID: NCT05305924 (https://classic.clinicaltrials.gov/show/NCT05305924)
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
NCT ID: NCT03796559 (https://classic.clinicaltrials.gov/show/NCT03796559)
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
NCT ID: NCT05524584 (https://classic.clinicaltrials.gov/show/NCT05524584)
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
NCT ID: NCT05693766 (https://classic.clinicaltrials.gov/show/NCT05693766)
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
NCT ID: NCT05748834 (https://classic.clinicaltrials.gov/show/NCT05748834)
Molecular Neuroimaging to Assess the Link Between Neuroinflammation and Cognitive Impairment in Breast Cancer
NCT ID: NCT04364672 (https://classic.clinicaltrials.gov/show/NCT04364672)
Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)
NCT ID: NCT05554354 (https://classic.clinicaltrials.gov/show/NCT05554354)
Decellularized, Whole Donor Nipple-Areola Complex Reconstruction Grafts
NCT ID: NCT04534010 (https://classic.clinicaltrials.gov/show/NCT04534010)
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
NCT ID: NCT05230810 (https://classic.clinicaltrials.gov/show/NCT05230810)
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
NCT ID: NCT05746897 (https://classic.clinicaltrials.gov/show/NCT05746897)
FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer
NCT ID: NCT04174352 (https://classic.clinicaltrials.gov/show/NCT04174352)
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
NCT ID: NCT03990896 (https://classic.clinicaltrials.gov/show/NCT03990896)
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
NCT ID: NCT04852887 (https://classic.clinicaltrials.gov/show/NCT04852887)
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
NCT ID: NCT06018337 (https://classic.clinicaltrials.gov/show/NCT06018337)
MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer
NCT ID: NCT05076760 (https://classic.clinicaltrials.gov/show/NCT05076760)
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
NCT ID: NCT05269381 (https://classic.clinicaltrials.gov/show/NCT05269381)
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
NCT ID: NCT04039230 (https://classic.clinicaltrials.gov/show/NCT04039230)
Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
NCT ID: NCT04762979 (https://classic.clinicaltrials.gov/show/NCT04762979)
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
NCT ID: NCT05111561 (https://classic.clinicaltrials.gov/show/NCT05111561)
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
NCT ID: NCT05458674 (https://classic.clinicaltrials.gov/show/NCT05458674)
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
NCT ID: NCT03368729 (https://classic.clinicaltrials.gov/show/NCT03368729)
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT ID: NCT05894239 (https://classic.clinicaltrials.gov/show/NCT05894239)
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
NCT ID: NCT05629585 (https://classic.clinicaltrials.gov/show/NCT05629585)
Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction
NCT ID: NCT05190978 (https://classic.clinicaltrials.gov/show/NCT05190978)
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
NCT ID: NCT02422641 (https://classic.clinicaltrials.gov/show/NCT02422641)
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
NCT ID: NCT06253520 (https://classic.clinicaltrials.gov/show/NCT06253520)
Cryoablation vs Lumpectomy in T1 Breast Cancers
NCT ID: NCT05505643 (https://classic.clinicaltrials.gov/show/NCT05505643)
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT ID: NCT05132582 (https://classic.clinicaltrials.gov/show/NCT05132582)
A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
NCT ID: NCT04072952 (https://classic.clinicaltrials.gov/show/NCT04072952)
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
NCT ID: NCT05092373 (https://classic.clinicaltrials.gov/show/NCT05092373)
ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy
NCT ID: NCT06185205 (https://classic.clinicaltrials.gov/show/NCT06185205)
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
NCT ID: NCT04704661 (https://classic.clinicaltrials.gov/show/NCT04704661)
TRUDI: TDXD+Durva in HER2+/Low IBC
NCT ID: NCT05795101 (https://classic.clinicaltrials.gov/show/NCT05795101)
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
NCT ID: NCT03975647 (https://classic.clinicaltrials.gov/show/NCT03975647)
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy
NCT ID: NCT05840211 (https://classic.clinicaltrials.gov/show/NCT05840211)
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
NCT ID: NCT03671044 (https://classic.clinicaltrials.gov/show/NCT03671044)
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
NCT ID: NCT05852691 (https://classic.clinicaltrials.gov/show/NCT05852691)
CD40 Agonist, Flt3 Ligand, and Chemotherapy in Triple Negative Breast Cancer
NCT ID: NCT05029999 (https://classic.clinicaltrials.gov/show/NCT05029999)
Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors
NCT ID: NCT05700669 (https://classic.clinicaltrials.gov/show/NCT05700669)
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
NCT ID: NCT03412877 (https://classic.clinicaltrials.gov/show/NCT03412877)
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
NCT ID: NCT05877599 (https://classic.clinicaltrials.gov/show/NCT05877599)
Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
NCT ID: NCT03095352 (https://classic.clinicaltrials.gov/show/NCT03095352)
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma
NCT ID: NCT04119024 (https://classic.clinicaltrials.gov/show/NCT04119024)
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT ID: NCT04862663 (https://classic.clinicaltrials.gov/show/NCT04862663)
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT ID: NCT05696626 (https://classic.clinicaltrials.gov/show/NCT05696626)
A Study to Investigate LYL797 in Adults With Solid Tumors
NCT ID: NCT05274451 (https://classic.clinicaltrials.gov/show/NCT05274451)
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT ID: NCT05296798 (https://classic.clinicaltrials.gov/show/NCT05296798)
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
NCT ID: NCT06103864 (https://classic.clinicaltrials.gov/show/NCT06103864)
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
NCT ID: NCT06105632 (https://classic.clinicaltrials.gov/show/NCT06105632)
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
NCT ID: NCT03589339 (https://classic.clinicaltrials.gov/show/NCT03589339)
RAPA-201 Therapy of Solid Tumors
NCT ID: NCT05144698 (https://classic.clinicaltrials.gov/show/NCT05144698)
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
NCT ID: NCT05374512 (https://classic.clinicaltrials.gov/show/NCT05374512)
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
NCT ID: NCT06110793 (https://classic.clinicaltrials.gov/show/NCT06110793)
A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants
NCT ID: NCT05963984 (https://classic.clinicaltrials.gov/show/NCT05963984)
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
NCT ID: NCT03424005 (https://classic.clinicaltrials.gov/show/NCT03424005)
Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System
NCT ID: NCT05291507 (https://classic.clinicaltrials.gov/show/NCT05291507)
SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells
NCT ID: NCT04150042 (https://classic.clinicaltrials.gov/show/NCT04150042)
VS-6766+Abema+Fulv in Met HR+/HER- BC
NCT ID: NCT05608252 (https://classic.clinicaltrials.gov/show/NCT05608252)
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
NCT ID: NCT05306340 (https://classic.clinicaltrials.gov/show/NCT05306340)
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
NCT ID: NCT05323955 (https://classic.clinicaltrials.gov/show/NCT05323955)
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT ID: NCT05382286 (https://classic.clinicaltrials.gov/show/NCT05382286)
A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer
NCT ID: NCT06145399 (https://classic.clinicaltrials.gov/show/NCT06145399)
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT ID: NCT05382299 (https://classic.clinicaltrials.gov/show/NCT05382299)
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC
NCT ID: NCT03562637 (https://classic.clinicaltrials.gov/show/NCT03562637)
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT ID: NCT05646862 (https://classic.clinicaltrials.gov/show/NCT05646862)
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
NCT ID: NCT05563220 (https://classic.clinicaltrials.gov/show/NCT05563220)
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
NCT ID: NCT04457596 (https://classic.clinicaltrials.gov/show/NCT04457596)
Onvansertib + Paclitaxel In TNBC
NCT ID: NCT05383196 (https://classic.clinicaltrials.gov/show/NCT05383196)
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
NCT ID: NCT05313191 (https://classic.clinicaltrials.gov/show/NCT05313191)
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
NCT ID: NCT05239143 (https://classic.clinicaltrials.gov/show/NCT05239143)
Testing a New Imaging Agent to Identify Cancer
NCT ID: NCT04692831 (https://classic.clinicaltrials.gov/show/NCT04692831)
OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer
NCT ID: NCT05949021 (https://classic.clinicaltrials.gov/show/NCT05949021)
Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer
NCT ID: NCT05163223 (https://classic.clinicaltrials.gov/show/NCT05163223)
A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer.
NCT ID: NCT05654623 (https://classic.clinicaltrials.gov/show/NCT05654623)
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT ID: NCT04550494 (https://classic.clinicaltrials.gov/show/NCT04550494)
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT ID: NCT05501886 (https://classic.clinicaltrials.gov/show/NCT05501886)
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
NCT ID: NCT04468061 (https://classic.clinicaltrials.gov/show/NCT04468061)
Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer
NCT ID: NCT04243616 (https://classic.clinicaltrials.gov/show/NCT04243616)
A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer
NCT ID: NCT05966584 (https://classic.clinicaltrials.gov/show/NCT05966584)
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
NCT ID: NCT05933395 (https://classic.clinicaltrials.gov/show/NCT05933395)
Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions
NCT ID: NCT04549571 (https://classic.clinicaltrials.gov/show/NCT04549571)
Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype
NCT ID: NCT05207709 (https://classic.clinicaltrials.gov/show/NCT05207709)
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
NCT ID: NCT04802759 (https://classic.clinicaltrials.gov/show/NCT04802759)
Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel
NCT ID: NCT04862585 (https://classic.clinicaltrials.gov/show/NCT04862585)
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
NCT ID: NCT06188520 (https://classic.clinicaltrials.gov/show/NCT06188520)
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT ID: NCT04975308 (https://classic.clinicaltrials.gov/show/NCT04975308)
Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)
NCT ID: NCT05751668 (https://classic.clinicaltrials.gov/show/NCT05751668)
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
NCT ID: NCT04319757 (https://classic.clinicaltrials.gov/show/NCT04319757)
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
NCT ID: NCT06239467 (https://classic.clinicaltrials.gov/show/NCT06239467)
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT ID: NCT06016738 (https://classic.clinicaltrials.gov/show/NCT06016738)
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
NCT ID: NCT04964934 (https://classic.clinicaltrials.gov/show/NCT04964934)
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
NCT ID: NCT02632448 (https://classic.clinicaltrials.gov/show/NCT02632448)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT ID: NCT05564377 (https://classic.clinicaltrials.gov/show/NCT05564377)
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection
NCT ID: NCT03746431 (https://classic.clinicaltrials.gov/show/NCT03746431)
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
NCT ID: NCT02830724 (https://classic.clinicaltrials.gov/show/NCT02830724)
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
NCT ID: NCT04771520 (https://classic.clinicaltrials.gov/show/NCT04771520)
Roll-over Study to Allow Continued Access to Ribociclib
NCT ID: NCT05161195 (https://classic.clinicaltrials.gov/show/NCT05161195)
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
NCT ID: NCT04042701 (https://classic.clinicaltrials.gov/show/NCT04042701)
DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT ID: NCT04567420 (https://classic.clinicaltrials.gov/show/NCT04567420)
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT ID: NCT06120283 (https://classic.clinicaltrials.gov/show/NCT06120283)
Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction
NCT ID: NCT03934905 (https://classic.clinicaltrials.gov/show/NCT03934905)
Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study
NCT ID: NCT05545150 (https://classic.clinicaltrials.gov/show/NCT05545150)
A Study of DB-1303 in Advanced/Metastatic Solid Tumors
NCT ID: NCT05150691 (https://classic.clinicaltrials.gov/show/NCT05150691)
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer
NCT ID: NCT05216432 (https://classic.clinicaltrials.gov/show/NCT05216432)
Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
NCT ID: NCT04925284 (https://classic.clinicaltrials.gov/show/NCT04925284)
Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer
NCT ID: NCT05498155 (https://classic.clinicaltrials.gov/show/NCT05498155)
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study
NCT ID: NCT05568472 (https://classic.clinicaltrials.gov/show/NCT05568472)
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
NCT ID: NCT04606446 (https://classic.clinicaltrials.gov/show/NCT04606446)
Study of DF1001 in Patients With Advanced Solid Tumors
NCT ID: NCT04143711 (https://classic.clinicaltrials.gov/show/NCT04143711)
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
NCT ID: NCT05483491 (https://classic.clinicaltrials.gov/show/NCT05483491)
Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
NCT ID: NCT04677816 (https://classic.clinicaltrials.gov/show/NCT04677816)
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab
NCT ID: NCT05082610 (https://classic.clinicaltrials.gov/show/NCT05082610)
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
NCT ID: NCT05150652 (https://classic.clinicaltrials.gov/show/NCT05150652)
A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer
NCT ID: NCT05909397 (https://classic.clinicaltrials.gov/show/NCT05909397)
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
NCT ID: NCT05215574 (https://classic.clinicaltrials.gov/show/NCT05215574)
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
NCT ID: NCT05070247 (https://classic.clinicaltrials.gov/show/NCT05070247)
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
NCT ID: NCT05467891 (https://classic.clinicaltrials.gov/show/NCT05467891)
Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NCT ID: NCT04913337 (https://classic.clinicaltrials.gov/show/NCT04913337)
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
NCT ID: NCT06328738 (https://classic.clinicaltrials.gov/show/NCT06328738)
PRE-I-SPY Phase I/Ib Oncology Platform Program
NCT ID: NCT05868226 (https://classic.clinicaltrials.gov/show/NCT05868226)
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
NCT ID: NCT05576077 (https://classic.clinicaltrials.gov/show/NCT05576077)
Study to Evaluate CCS1477 in Advanced Tumours
NCT ID: NCT03568656 (https://classic.clinicaltrials.gov/show/NCT03568656)
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
NCT ID: NCT05035407 (https://classic.clinicaltrials.gov/show/NCT05035407)
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
NCT ID: NCT06270706 (https://classic.clinicaltrials.gov/show/NCT06270706)
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
NCT ID: NCT06022029 (https://classic.clinicaltrials.gov/show/NCT06022029)
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
NCT ID: NCT05765851 (https://classic.clinicaltrials.gov/show/NCT05765851)
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT ID: NCT05277051 (https://classic.clinicaltrials.gov/show/NCT05277051)
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients
NCT ID: NCT05898399 (https://classic.clinicaltrials.gov/show/NCT05898399)
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT ID: NCT06112379 (https://classic.clinicaltrials.gov/show/NCT06112379)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT ID: NCT04585750 (https://classic.clinicaltrials.gov/show/NCT04585750)
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
NCT ID: NCT05252390 (https://classic.clinicaltrials.gov/show/NCT05252390)
BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer
NCT ID: NCT06085742 (https://classic.clinicaltrials.gov/show/NCT06085742)
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
NCT ID: NCT04140526 (https://classic.clinicaltrials.gov/show/NCT04140526)
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
NCT ID: NCT04225117 (https://classic.clinicaltrials.gov/show/NCT04225117)
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors
NCT ID: NCT05593094 (https://classic.clinicaltrials.gov/show/NCT05593094)
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
NCT ID: NCT05650879 (https://classic.clinicaltrials.gov/show/NCT05650879)
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
NCT ID: NCT05864144 (https://classic.clinicaltrials.gov/show/NCT05864144)
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
NCT ID: NCT05887492 (https://classic.clinicaltrials.gov/show/NCT05887492)
A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors
NCT ID: NCT06157892 (https://classic.clinicaltrials.gov/show/NCT06157892)
PF-07104091 as a Single Agent and in Combination Therapy
NCT ID: NCT04553133 (https://classic.clinicaltrials.gov/show/NCT04553133)
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
NCT ID: NCT05417594 (https://classic.clinicaltrials.gov/show/NCT05417594)
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT ID: NCT06257264 (https://classic.clinicaltrials.gov/show/NCT06257264)
A Study of NX-1607 in Adults With Advanced Malignancies
NCT ID: NCT05107674 (https://classic.clinicaltrials.gov/show/NCT05107674)
A Study of SGN-PDL1V in Advanced Solid Tumors
NCT ID: NCT05208762 (https://classic.clinicaltrials.gov/show/NCT05208762)
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), in Subjects With Tumors With Oncogene Amplifications
NCT ID: NCT05827614 (https://classic.clinicaltrials.gov/show/NCT05827614)
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
NCT ID: NCT05262400 (https://classic.clinicaltrials.gov/show/NCT05262400)
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT ID: NCT02488967 (https://classic.clinicaltrials.gov/show/NCT02488967)
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
NCT ID: NCT06065059 (https://classic.clinicaltrials.gov/show/NCT06065059)
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
NCT ID: NCT05325866 (https://classic.clinicaltrials.gov/show/NCT05325866)
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
NCT ID: NCT04569747 (https://classic.clinicaltrials.gov/show/NCT04569747)
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
NCT ID: NCT04722692 (https://classic.clinicaltrials.gov/show/NCT04722692)
A Beta-only IL-2 ImmunoTherapY Study
NCT ID: NCT05086692 (https://classic.clinicaltrials.gov/show/NCT05086692)
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
NCT ID: NCT05537740 (https://classic.clinicaltrials.gov/show/NCT05537740)
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.